Efficacy and Safety of Chimeric Antigen Receptor-T Cells in the Treatment of B Cell Lymphoma: A Systematic Review and Meta-Analysis
Non-Hodgkin lymphoma (NHL) represents a group of malignant tumors originating from B lymphocytes, T lymphocytes, and natural killer cells. Among these, B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL), account for a significant proportion of cases. Conventional treatments, including chemotherapy and autologous stem cell transplantation (ASCT), have shown limited efficacy in relapsed or refractory cases. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising approach, demonstrating high remission rates and safety in treating B-cell malignancies. This systematic review and meta-analysis aim to evaluate the efficacy and safety of CAR-T cell therapy in B-cell lymphoma, providing evidence for its clinical application.
Background
B-cell lymphomas, especially DLBCL, are among the most common subtypes of NHL. Despite advancements in treatment, a significant proportion of patients experience relapse or refractory disease, leading to poor prognosis. CAR-T cell therapy, which involves genetically engineering T cells to express a tumor-targeting chimeric antigen receptor (CAR), has shown potential in addressing these challenges. The most common target for CAR-T therapy in B-cell lymphoma is CD19, a transmembrane glycoprotein expressed throughout B-cell differentiation and malignant transformation. However, other targets such as CD20, CD22, and kappa light chain have also been explored.
Methods
A comprehensive search of databases including PubMed, Embase, and Cochrane was conducted up to July 2019. Studies were included if they reported on CAR-T cell therapy for B-cell lymphoma, provided complete or partial data on patient demographics, pathological type, target antigen, co-stimulatory molecule, and conditioning chemotherapy, and reported efficacy and safety outcomes. Two independent reviewers extracted data, and discrepancies were resolved through discussion with a third reviewer. The Cochrane Collaboration risk of bias tool was used to assess study quality.
Meta-analysis 1 focused on the efficacy of CAR-T cell therapy, measuring the response rate (RR) and complete remission rate (CRR). Subgroup analyses were performed based on age, pathological type, target antigen, co-stimulatory molecule, and conditioning chemotherapy. Meta-analysis 2 evaluated the safety of CAR-T cell therapy, with the incidence rates of cytokine release syndrome (CRS) and neurotoxicity as primary outcomes.
Results
Seventeen studies involving 280 patients were included in the analysis. The overall RR and CRR for CAR-T cell therapy in B-cell lymphoma were 63% and 39%, respectively. Subgroup analyses revealed higher efficacy in patients aged 65 years or older, those with DLBCL, those treated with non-CD19 target antigens, those receiving co-stimulatory molecules other than CD28 (such as 4-1BB or 4-1BB+CD28), and those treated with cyclophosphamide/fludarabine (Cy/Flu) conditioning chemotherapy.
The incidence rates of grade 3/4 CRS and neurotoxicity were 21% and 9%, respectively. Although these rates were elevated, most adverse events were reversible, and the risk of fatal outcomes was minimal. Sensitivity analysis identified significant heterogeneity in some studies, but the overall findings remained robust.
Discussion
CAR-T cell therapy has demonstrated significant efficacy in treating B-cell lymphoma, particularly in cases that are refractory to conventional treatments. The higher RR and CRR observed in older patients, those with DLBCL, and those treated with non-CD19 target antigens and alternative co-stimulatory molecules suggest that these factors may enhance the therapeutic impact of CAR-T cells. The use of Cy/Flu conditioning chemotherapy also appeared to improve outcomes, likely due to its lymphodepleting effects, which enhance CAR-T cell expansion and persistence.
The safety profile of CAR-T cell therapy, while concerning due to the high incidence of CRS and neurotoxicity, is manageable with appropriate interventions. Tocilizumab, an anti-IL-6 receptor antibody, has become the first-line treatment for CRS, while steroids are commonly used for neurotoxicity. The reversibility of these adverse events and the low risk of fatal outcomes support the clinical application of CAR-T cell therapy in B-cell lymphoma.
Limitations of this meta-analysis include the predominance of single-arm studies with small sample sizes, which may affect the strength of the conclusions. The heterogeneity observed in some subgroup analyses may be attributed to variations in study design, patient characteristics, and CAR-T cell dosing. Additionally, the potential for publication bias, as studies with positive results are more likely to be published, may overestimate the efficacy of CAR-T cell therapy.
Future research should focus on large multi-center randomized controlled trials to validate these findings and explore the optimal treatment protocols for CAR-T cell therapy in B-cell lymphoma. Further investigation into the mechanisms underlying the differential efficacy observed in various subgroups may also inform the development of more targeted and effective CAR-T cell therapies.
Conclusion
This systematic review and meta-analysis confirm the efficacy and safety of CAR-T cell therapy in treating B-cell lymphoma. The higher RR and CRR observed in specific subgroups, along with the manageable nature of adverse events, support the clinical application of this innovative treatment. However, clinicians should remain vigilant for the occurrence of CRS and neurotoxicity, providing timely interventions to mitigate these risks. Continued research and clinical trials are essential to optimize CAR-T cell therapy and improve outcomes for patients with B-cell lymphoma.
doi.org/10.1097/CM9.0000000000000568
Was this helpful?
0 / 0